Merck KGaA refines Western European life science production site network
Company to invest €90 million and cut 200 jobs.
Merck KGaA has announced the next phase in its continued efforts to drive operational excellence and improve efficiency of its Life Science business. The current site network in Western Europe will be refined, while the company invests €90 million in four sites in Germany, Switzerland and France. Since 2010, the Life Science business of Merck has consolidated 18 manufacturing sites to further simplify operations and establish Centers of Excellence.
The Life Science business will implement the following changes:
“Centralizing filling of small quantities and their distribution will continue to increase our speed and responsiveness to customer requests. This is something that the acquired Sigma-Aldrich excelled in and we see positive impacts of this effort already in North America,” said Udit Batra, Member of the Executive Board and CEO, Life Science.
Batra added: “Our responsibility to customers as well as our employees remains of the utmost importance. As our strong history has proven, by partnering with employee representative bodies across the respective countries, we are committed to fair and acceptable solutions for those impacted by relocation plans.”
“By continuously optimizing our site network, Merck can better serve our customers and focus investments that develop capacity and capability most effectively and efficiently across our manufacturing and distribution operations,” said Christos Ross, Executive Vice President of Integrated Supply Chain Operations, Life Science. “We have most recently been optimizing our capabilities with network updates at our sites through the USA such as St Louis and Massachusetts, and around the globe in China, Cork Ireland and Japan, to name a few. As demonstrated in these network optimizations, we will work across all sites to ensure a smooth transition and no customer disruption.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance